LUDWIG ENTERPRISES, INC.

Ludwig Enterprises, Inc. is an early-stage genomic technology company focused on developing screening tests for chronic inflammatory conditions and cancers. The company's primary focus centers on identifying dynamic mRNA expression patterns rather than static DNA alterations to detect early disease activity. Its lead product candidate is the Revealia™ Breast test, a non-invasive screening tool designed to evaluate inflammation-related molecular signatures using a 48-gene biomarker panel and proprietary ensemble machine-learning algorithms. Ludwig plans to distribute at-home cheek swab collection kits through a business-to-business-to-consumer model that incorporates certified genetic counselors and independent laboratory partnerships.

The company operates within the United States and has collected clinical samples across more than 40 clinical sites through multi-site research programs. It also maintains pending patent applications across multiple international jurisdictions, including North America, Europe, and Asia. Ludwig Enterprises maintains its principal executive offices in Miami, Florida.

Summary of the business section of Ludwig Enterprises's latest annual report, written by StockData.